The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial

Annemarie L Lee, Catherine J Hill, Nola Cecins, Sue Jenkins, Christine F McDonald, Angela T Burge, Linda Rautela, Robert G Stirling, Philip J Thompson, Anne E Holland, Annemarie L Lee, Catherine J Hill, Nola Cecins, Sue Jenkins, Christine F McDonald, Angela T Burge, Linda Rautela, Robert G Stirling, Philip J Thompson, Anne E Holland

Abstract

Background: Exercise training is recommended for non-cystic fibrosis (CF) bronchiectasis, but the long-term effects are unclear. This randomised controlled trial aimed to determine the effects of exercise training and review of airway clearance therapy (ACT) on exercise capacity, health related quality of life (HRQOL) and the incidence of acute exacerbations in people with non-CF bronchiectasis.

Methods: Participants were randomly allocated to 8 weeks of supervised exercise training and review of ACT, or control. Primary outcomes of exercise capacity and HRQOL (Chronic respiratory disease questionnaire) and secondary outcomes of cough-related QOL (Leicester cough questionnaire) and psychological symptoms (Hospital anxiety and depression scale) were measured at baseline, following completion of the intervention period and at 6 and 12 months follow up. Secondary outcomes of the exacerbation rate and time to first exacerbation were analysed over 12 months.

Results: Eighty-five participants (mean FEV1 74% predicted; median Modified Medical Research Council Dyspnoea grade of 1 (IQR [1-3]) were included. Exercise training increased the incremental shuttle walk distance (mean difference to control 62 m, 95% CI 24 to 101 m) and the 6-minute walking distance (mean difference to control 41 m, 95% CI 19 to 63 m), but these improvements were not sustained at 6 or 12 months. Exercise training reduced dyspnoea (p = 0.009) and fatigue (p = 0.01) but did not impact on cough-related QOL or mood. Exercise training reduced the frequency of acute exacerbations (median 1[IQR 1-3]) compared to the control group (2[1-3]) over 12 months follow up (p = 0.012), with a longer time to first exacerbation with exercise training of 8 months (95% CI 7 to 9 months) compared to the control group (6 months [95% CI 5 to 7 months], p = 0.047).

Conclusions: Exercise training in bronchiectasis is associated with short term improvement in exercise capacity, dyspnoea and fatigue and fewer exacerbations over 12 months.

Trial registry: ClinicalTrials.gov (NCT00885521).

Figures

Figure 1
Figure 1
Flow of participants.
Figure 2
Figure 2
Change in incremental shuttle walk distance (A) and 6-minute walk distance (B). Data are mean (95% CI), *p < 0.05, exercise vs control group.
Figure 3
Figure 3
Change in health-related quality of life – Chronic Respiratory Disease Questionnaire domains, Data are mean (95% CI), *p < 0.05, exercise vs control group.
Figure 4
Figure 4
Time to first exacerbation, p = 0.047.

References

    1. Barker A. Bronchiectasis. N Engl J Med. 2002;346:1383–1393. doi: 10.1056/NEJMra012519.
    1. King P, Holdsworth SR, Freezer N, Villanueva E, Holmes PW. Characteristation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100:2183–2189. doi: 10.1016/j.rmed.2006.03.012.
    1. Martinez Garcia M, Perpina Tordera M, Roman Sanchez P, Soler Cataluna JJ. Quality of life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128:739–745. doi: 10.1378/chest.128.2.739.
    1. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, Quittner AL, Espildora F. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual Life Res. 2013;22:597–605. doi: 10.1007/s11136-012-0188-5.
    1. Chang A, Bilton D. Exacerbation in cystic fibrosis: 4-Non cystic fibrosis bronchiectasis. Thorax. 2008;63:269–276. doi: 10.1136/thx.2006.060913.
    1. Finklea J, Khan G, Thomas S, Song J, Myers D, Arroliga AC. Predictors of mortality in hospitalised patients with acute exacerbation of bronchiectasis. Respir Med. 2010;104:816–821. doi: 10.1016/j.rmed.2009.11.021.
    1. Martinez-Garcia M, Soler-Cataluna J, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565–1572. doi: 10.1378/chest.07-0490.
    1. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–439. doi: 10.1378/chest.1389598.
    1. Seitz AE, Olivier KN, Steiner CA, Montes De Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010;138:944–949. doi: 10.1378/chest.10-0099.
    1. Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia, 2010. [ ]
    1. Joish V, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy. 2013;11:299–304. doi: 10.1007/s40258-013-0027-z.
    1. Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte J, Rademacher J. Bronchiectasis-associated hospitalisation in Germany, 2005–2011 - a population-based study of disease burden and trends. PLoS One. 2013;8:e71109. doi: 10.1371/journal.pone.0071109.
    1. Pasteur M, Bilton D, Hill A, Stockley RA, Wilson R, Pasteur MC, Herriot R, Hansel DM, Bush A, Cornford C, Willcox L, Bilton D, Parry GW, Sonnappa S, Wallis C, French J, Sinfield F, Harvey A, Bott J, Pryor J, Hill AT, Greenstone M, Cunningham S, Spencer DA, Emmanue X, Kalima P, Heslop K, Elborn S, Carr S, Cole B. British Thoracic Society guidelines for non-CF bronchiectasis. Thorax. 2010;65:i1–i58. doi: 10.1136/thx.2010.136119.
    1. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland A, Lareau SC, Man MD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, Van Der Palen J, Troosters T, Janssen DJ, Collins E, Garcia Aymerich J, Brooks D, Fahy BF. et official American thoracic society/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13–e64. doi: 10.1164/rccm.201309-1634ST.
    1. Ong H, Lee A, Hill C, Holland AE, Denehy L. Effects of pulmonary rehabilitation in bronchiectasis: a retrospective study. Chron Respir Dis. 2011;8:21–30. doi: 10.1177/1479972310391282.
    1. Zan Zellar M, Caetano P, Amorim A, Viana P, Martins P, Gaspar L, Hespanhol V, Gomes I. Pulmonary rehabilitation in patients with bronchiectasis: pulmonary function, arterial blood gases and the 6-minute walk test. J Cardiopulm Rehabil Prev. 2012;32:278–283. doi: 10.1097/HCR.0b013e3182631314.
    1. Newall C, Stockley R, Hill S. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005;60:943–948. doi: 10.1136/thx.2004.028928.
    1. Mandal P, Sidhu M, Kope L, Pollock W, Stevenson LM, Pentland JL, Turnbull K, MacQuarrie S, Hill AT. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med. 2012;106:1647–1654. doi: 10.1016/j.rmed.2012.08.004.
    1. Griffiths T, Phillips C, Davies S, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation program. Thorax. 2001;56:779–784. doi: 10.1136/thorax.56.10.779.
    1. Lee A, Cecins N, Hill C, Holland AE, Rautela L, Stirling RG, Thompson P, McDonald CF, Jenkins S. The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: protocol for a randomised controlled trial. BMC Pulm Med. 2010;10:1–7. doi: 10.1186/1471-2466-10-1.
    1. Mahler D, Wells C. Evaluation of clinical methods for rating dyspnea. Chest. 1998;93:580–586.
    1. Global initative for chronic obstructive lung disease: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2013. [ ]
    1. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention . 2012. [ ]
    1. Pryor JA, Prasad SA. In: Physiotherapy for Respiratory and Cardiac problems. Pryor JA, Prasad S, editor. United Kingdom: Elsevier; 2008. Physiotherapy problems; pp. 398–394.
    1. Alison J, Barrack C, Cafarella P, Frith P, Hanna C, Hill CJ, Holland AE, Jenkins S, Meinhardt J, McDonald CF, McKeough Z, Patman S, Ross J, Seale H, Shoemaker C, Spencer L, Allan H, Banks S, Barrett S, Beeley H, Blake J, Boden I, Cecins N, Cockram J, Herd K, Hill K, Langdon C, Lee AL, Leung R, McNamara R, Pulmonary rehabilitation toolkit. [ ]
    1. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntye N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T. on behalf of the ATS/ERS Pulmonary rehabilitation writing committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–1413. doi: 10.1164/rccm.200508-1211ST.
    1. Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR. Estimating maximal work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008;89:1782–1787. doi: 10.1016/j.apmr.2008.01.020.
    1. Holland A, Hill C, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63:549–554. doi: 10.1136/thx.2007.088070.
    1. Australian Government, Department of Health. Physical Activity guidelines. 2013. [ ]
    1. Singh S, Morgan M, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airway obstruction. Thorax. 1992;47:1019–1024. doi: 10.1136/thx.47.12.1019.
    1. Williams J, Singh S, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) Thorax. 2001;56:954–959. doi: 10.1136/thorax.56.12.954.
    1. American Thoracic Society. Guidelines for the 6-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
    1. Murray M, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34:125–131. doi: 10.1183/09031936.00160508.
    1. Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Pyschiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Hawthorn G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQOL) measures. Aust NZ J Public Health. 2005;29:136–142. doi: 10.1111/j.1467-842X.2005.tb00063.x.
    1. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21:167–189. doi: 10.1016/S0197-2456(00)00046-5.
    1. Miller ME, Morgan TM, Espeland MA, Emerson SS. Group comparisons involving missing data in clinical trials: a comparison of estimates and power (size) for some simple approaches. Stat Med. 2001;20:2383–2397. doi: 10.1002/sim.904.
    1. Schultz KF, Altman DG, Moher D. the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.
    1. Santamato A, Ranieri M, Panza F, Frisardi V, Marvulli R, Filoni S, Cisari C, Fiore P. Pulmonary rehabilitation for patients with bronchiectasis: case reports. Eur J Phys Rehabil Med. 2012;48:293–298.
    1. Akimoto T, Kumai Y, Hayashi E, Hayashi E, Murakami H, Soma R, Kuno S, Kono I. Effects of 12 months of exercise training on salivary secretory IgA levels in elderly subjects. Brit J Sports Med. 2003;37:76–79. doi: 10.1136/bjsm.37.1.76.
    1. Dwyer T, Alison J, McKeough ZJ, Daviskas E, Bye PT. Effects of exercise on respiratory flow and sputum properties in patients with cystic fibrosis. Chest. 2011;139:870–877. doi: 10.1378/chest.10-1158.
    1. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roison R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15–19. doi: 10.1136/thorax.57.1.15.
    1. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34:843–849. doi: 10.1183/09031936.00003709.
    1. Puhan M, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Sciurba F. The minimal important difference of exercise tests in severe COPD. Eur Respir J. 2011;37:784–790. doi: 10.1183/09031936.00063810.
    1. King PT, Holdsworth SR, Freezer NJ, Vallanueva E, Farmer MW, Guy P, Holmes PW. Lung diffusing capacity in adult bronchiectasis: a longitudinal study. Respir Care. 2010;55:1686–1692.
    1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallaher M, Holmes PW. Outcome in adult bronchiectasis. Int J of Chron Obstruct Pulmon Dis. 2005;2:27–34. doi: 10.1081/COPD-200050685.
    1. Tantucci C, Modina D. Lung function decline in COPD. Int J of Chron Obstruct Pulmon Dis. 2012;7:95–99.
    1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI.
    1. Beauchamp M, Janaudis-Ferreira T, Goldstein R, Brooks D. Optimal duration of pulmonary rehabilitation for individuals with COPD - a systematic review. Chron Respir Dis. 2011;8:129–140.
    1. Pitta F, Troosters T, Probst V, Langer D, Decramer M, Gosselink R. Are patients with COPD more active after PR. Chest. 2008;134:273–280. doi: 10.1378/chest.07-2655.
    1. Wempe J, Wijkstra P. The influence of rehabilitation on behaviour modification in COPD. Patient Educ Couns. 2004;52:237–241. doi: 10.1016/S0738-3991(03)00097-1.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever